EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

AMH as a marker for resumption of ovarian function after chemotherapy: an IPD meta-analysis and systematic review

Charissa van Zwol-Janssens, Mandy van M Rosmalen, Joop S E Laven, Kazem Nasserinejad, Jenny A Visser, Richard A Anderson, Irit Ben-Aharon, Thomas Freour, Kathryn J Ruddy, H Irene Su, Yvonne V Louwers, Agnes Jager

Cancer Treatment Reviews · 2026

DOI: 10.1016/j.ctrv.2025.103068 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cancer Treatment Reviews, 2026. Verfasst von Charissa van Zwol-Janssens und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Erasmus MC, University Medical Center Rotterdam, the Ne…. Hauptthemen laut MEDLINE: Anti-Mullerian Hormone, Breast Neoplasms, Ovary, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In premenopausal women with breast cancer, chemotherapy often leads to amenorrhea that could be temporary or permanent. Anti-Müllerian hormone (AMH) is a potential biomarker predicting resumption of ovarian function, an outcome that aids in the decision making for endocrine therapy. This study aimed to determine the predictive value of pre-chemotherapy AMH levels for resumption of ovarian function. METHODS: We conducted a systematic review and individual patient data (IPD) meta-analysis. Online databases were searched using terms including: AMH, prediction, menses, menses recovery, amenorrhea, chemotherapy-related amenorrhea, anovulation, menopause, infertility, ovarian reserve, premenopausal, breast cancer, chemotherapy. The study protocol was registered with PROSPERO (CRD42021233966). RESULTS: The systematic review included 31 studies, with 26 contributing to the meta-analysis. Eleven studies provided IPD from 1,029 women. Ovarian function resumption rates varied from 24 % to 61 % depending on follow-up time. Pre-chemotherapy AMH was significantly higher in women whose ovarian function resumed, standardized mean difference 0.94 (95 % CI 0.65-1.22) and showed good predictive ability for resumption of ovarian function (AUC 0.79-0.83). However, the identified cut-off values for pre-chemotherapy AMH gave high false negative rates and differed a lot between studies which was much determined by follow-up time, age and used AMH assay. CONCLUSION: Pre-chemotherapy AMH shows association with ovarian function resumption, but a clinically reliable cut-off across assays could not be established using individual patient data. Therefore, due to high inter-assay variability, AMH is not suitable for optimizing endocrine therapy in premenopausal breast cancer patients at this time. Standardizing AMH assays can help in further research into a cut-off value.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Mullerian HormoneBreast NeoplasmsOvaryAntineoplastic AgentsHumansFemaleBiomarkersOvarian ReservePremenopause

Stichwörter der Autor:innen

Breast cancerChemotherapy induced amenorrheaOvarian functionPremenopausal

Substanzen

Anti-Mullerian HormoneBiomarkersAntineoplastic Agents

Autor:innen und Institutionen

  • Division Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Erasmus MC, University Medical Center Rotterdam, the Netherlands. Electronic address: c.janssens@erasmusmc.nl.
  • Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University MC, Rotterdam, the Netherlands.
  • Division Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Erasmus MC, University Medical Center Rotterdam, the Netherlands.
  • Division of Statistics, Department of Hematology, Erasmus MC Cancer Institute, Erasmus University MC, Rotterdam, the Netherlands.
  • Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
  • Centre for Reproductive Health, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh EH16 4UU, United Kingdom.

Zitieren

APA

van Zwol-Janssens, C., van M Rosmalen, M., Laven, J. S. E., Nasserinejad, K., Visser, J. A., Anderson, R. A., Ben-Aharon, I., Freour, T., Ruddy, K. J., Su, H. I., Louwers, Y. V., & Jager, A. (2026). AMH as a marker for resumption of ovarian function after chemotherapy: an IPD meta-analysis and systematic review. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2025.103068

Vancouver

van Zwol-Janssens C, van M Rosmalen M, Laven JSE, Nasserinejad K, Visser JA, Anderson RA, et al. AMH as a marker for resumption of ovarian function after chemotherapy: an IPD meta-analysis and systematic review. Cancer Treatment Reviews. 2026. doi:10.1016/j.ctrv.2025.103068

BibTeX
@article{vanZwolJanssens2026,
  author = {van Zwol-Janssens, Charissa and van M Rosmalen, Mandy and Laven, Joop S E and Nasserinejad, Kazem and Visser, Jenny A and Anderson, Richard A and Ben-Aharon, Irit and Freour, Thomas and Ruddy, Kathryn J and Su, H Irene and Louwers, Yvonne V and Jager, Agnes},
  title = {AMH as a marker for resumption of ovarian function after chemotherapy: an IPD meta-analysis and systematic review},
  journal = {Cancer Treatment Reviews},
  year = {2026},
  doi = {10.1016/j.ctrv.2025.103068}
}
Kostenlos starten →